News
-
-
-
PRESS RELEASE
ARTCLINE secures additional €3.4 million in funds to support commercialization of its ARTICE® immune cell therapy for treatment of septic shock
ARTCLINE secures €3.4 million to support commercialization of ARTICE® immune cell therapy for septic shock. New financing from investors like MBG MV -
-
-
PRESS RELEASE
ARTCLINE achieves milestone in septic shock: Patient recruitment for the ReActIF-ICE study successfully completed
ARTCLINE completes patient recruitment for ReActIF-ICE study in septic shock, evaluating ARTICE® immune cell therapy. Study results to be presented at DIVI Congress Dec. 2026 -
-
-
PRESS RELEASE
ARTCLINE appoints Peter Llewellyn-Davies as Chairman of the Supervisory Board and accelerates commercialization of innovative sepsis therapy
ARTCLINE appoints Peter Llewellyn-Davies as Chairman of the Supervisory Board, accelerating commercialization of innovative sepsis therapy with ARTICE® therapy for immune dysfunction in septic shock -
